Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANITSCHKOW: Evolocumab for arterial wall inflammation in patients with elevated lipoprotein(a)
NL-OMON46210Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hyperlipidemia and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Amgen. Started Apr 2016; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
hyperlipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON46210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46210.